ArticleMicroorganisms2021
Engraftment of Bacteria after Fecal Microbiota Transplantation Is Dependent on Both Frequency of Dosing and Duration of Preparative Antibiotic Regimen.
Article in Microorganisms, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 36 citations in OpenAlex.
- Neoadjuvant vidutolimod and nivolumab in high-risk resectable melanoma: A prospective phase II trial.Cancer cell · 2024Trial
- From gut dysbiosis to eubiosis: understanding microbiome recovery as an ecological process.Gut microbes · 2026Review
- Targeting the Human Gut Microbiota-Between Conventional Therapy and Precision Genetic Engineering.Nutrients · 2026Review
- Rhamnocitrin Ameliorates the Intestinal Fibrosis in DSS-Induced Colitis Mice by Modulating Host-Metabolites and Remodeling the Gut Microbiome.Antioxidants (Basel, Switzerland) · 2026Article
- Advance Microbiota Transplantation: A Novel Addition-Subtraction Paradigm for Optimising Faecal Microbiota Transplantation.Microbial biotechnology · 2026Review
- Effect of Gut Microbiota Alteration on Colorectal Cancer Progression in an In Vivo Model: Histopathological and Immunological Evaluation.Current issues in molecular biology · 2025Article
- Fucoidan Therapy for Extraintestinal Diseases: Targeting the Microbiota-Gut-Organ Axes.Biomolecules · 2025Review
- A review of engraftment assessments following fecal microbiota transplant.Gut microbes · 2025Review
- Fecal Microbiota Transplantation in Alzheimer's Disease: Mechanistic Insights Through the Microbiota-Gut-Brain Axis and Therapeutic Prospects.Microorganisms · 2025Review
- Antibiotic-Induced Microbial Dysbiosis Worsened Outcomes in the Activity-Based Anorexia Model.The International journal of eating disorders · 2025Article
- Advances in Fecal Microbiota Transplantation for Gut Dysbiosis-Related Diseases.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Review
- Shared environments complicate the use of strain-resolved metagenomics to infer microbiome transmission.Microbiome · 2025Article
- Fecal microbiota transplantation: application scenarios, efficacy prediction, and factors impacting donor-recipient interplay.Frontiers in microbiology · 2025Review
- Fecal microbiota transplants facilitate post-antibiotic recovery of gut microbiota in cheetahs (Acinonyx jubatus).Communications biology · 2024Article
- Shared environments complicate the use of strain-resolved metagenomics to infer microbiome transmission.bioRxiv : the preprint server for biology · 2024Article
- Fecal microbial transplants as investigative tools in cancer.American journal of physiology. Gastrointestinal and liver physiology · 2024Review
- A synbiotic of Anaerostipes caccae and lactulose prevents and treats food allergy in mice.Cell host & microbe · 2024Article
- Developing the Common Marmoset as a Translational Geroscience Model to Study the Microbiome and Healthy Aging.Microorganisms · 2024Review
- Review
- What we need to know about the germ-free animal models.AIMS microbiology · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The gut microbiota has emerged as a key mediator of human physiology, and germ-free mice have been essential in demonstrating a role for the microbiome in disease. Preclinical models using conventional mice offer the advantage of working with a mature immune system. However, optimal protocols for fecal microbiota transplant (FMT) engraftment in conventional mice are yet to be established. Conventional BALB/c mice were randomized to receive 3-day (3d) or 3-week (3w) antibiotic (ABX) regimen in their drinking water followed by 1 or 5-daily FMTs from a human donor. Fecal samples were collected longitudinally and characterized using 16S ribosomal RNA (rRNA) sequencing. Semi-targeted metabolomic profiling of fecal samples was also done with liquid chromatography-mass spectrometry (LC-MS). Lastly, we sought to confirm our findings in BKS mice. Recovery of baseline diversity scores were greatest in the 3d groups, driven by re-emergence of mouse commensal microbiota, whereas the most resemblance to donor microbiota was seen in the 3w + 5-FMT group. Amplicon sequence variants (ASVs) that were linked to the input material (human ASVs) engrafted to a significantly greater extent when compared to mouse ASVs in the 3-week groups but not the 3-day groups. Lastly, comparison of metabolomic profiles revealed distinct functional profiles by ABX regimen. These results indicate successful model optimization and emphasize the importance of ABX duration and frequency of FMT dosing; the most stable and reliable colonization by donor ASVs was seen in the 3wk + 5-FMT group.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.